Who can access testosterone therapy in the US, and how?

Testosterone replacement therapy has grown into a rapidly expanding market in the United States over the past decade. But who can actually access it, and how, depends on a regulatory landscape that is more complicated than most people realise.

In the US, testosterone is classified as a Schedule III controlled substance under the Controlled Substances Act, meaning it does not carry the high abuse risk of drugs like heroin or cocaine, but it is still subject to strict prescribing rules due to its potential for misuse. That classification is the key distinction between testosterone and freely available over-the-counter supplements.

Under the traditional medical pathway, a doctor can only prescribe testosterone if blood tests confirm "clinically low" testosterone levels accompanied by symptoms such as fatigue, reduced libido, or loss of muscle mass. This condition is known medically as hypogonadism, and treatment is typically managed by an endocrinologist or urologist.

In recent years, telehealth clinics have become a fast-growing alternative pathway. These platforms let patients get blood work done at home and receive a prescription after a brief consultation with a doctor, an approach that broadens access while skipping some steps of the traditional in-person exam process.

That expanded access has sparked debate among both patient advocates and physicians. Supporters argue the model is a lifeline for men with genuine testosterone deficiency who cannot reach a specialist due to geography or cost. Critics contend that some telehealth platforms are prescribing to men whose testosterone levels sit at the borderline or within the normal range.

Access to testosterone therapy operates under a different regulatory and insurance landscape for transgender men. Trans patients using testosterone as part of gender-affirming care can face widely varying approval processes depending on their state and insurance policy; some states have passed laws restricting access to this care, while others have expanded coverage.

Insurance coverage is another variable. Testosterone therapy is typically covered for patients formally diagnosed with hypogonadism, but coverage is often denied for what's colloquially called "low T" that does not meet the clinical threshold, pushing some patients toward out-of-pocket payment or telehealth options instead.

The treatment itself requires ongoing monitoring: patients on testosterone are generally advised to have periodic checks of blood counts, prostate health, and cardiovascular risk factors, since the therapy has been linked to elevated red blood cell counts and other side effects.

Regulators are watching telehealth testosterone prescribing practices closely. Several state medical boards have issued warnings about platforms prescribing without adequate clinical evaluation, though no consistent national standard has yet emerged.

In the end, there is no single path to accessing testosterone in the US: it runs from traditional endocrinology exams to telehealth platforms, from gender-affirming care clinics to insurance approval processes, and which path is available largely depends on a patient's diagnosis, insurance, and the state they live in.